Blue Crest Capital Management LTD Galectin Therapeutics Inc Transaction History

Blue Crest Capital Management LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$3.61 - $5.0 $163,460 - $226,400	-45,280 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$3.86 - $6.02 $52,750 - $82,269	13,666 Added 43.23%	45,280 $231,000
Q4 2018 Feb 14, 2019	BUY	$3.43 - $5.74 $108,436 - $181,464	31,614 New	31,614 $108,000
Q2 2018 Aug 14, 2018	SELL	$3.16 - $9.16 $320,442 - $928,878	-101,406 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$3.78 - $5.97 $383,314 - $605,393	101,406 New	101,406 $481,000

9.69M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $73.7M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Blue Crest Capital Management LTD, based on Form 13F filings with the SEC.

Stay updated on Blue Crest Capital Management LTD with notifications on news.